BIOMAT Database Logo BIOMAT Database Logo

The emerging safety profile of JAK inhibitors in rheumatic disease. 2017

Kevin L Winthrop

UI MeSH Term Description Entries

Related Publications

Kevin L Winthrop
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
September 2023, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Kevin L Winthrop
Emerging drug profile: JAK inhibitors.
May 2024, Leukemia & lymphoma,
Kevin L Winthrop
Safety profile of JAK inhibitors: a focus on baricitinib.
June 2020, The Lancet. Rheumatology,
Kevin L Winthrop
JAK inhibitors: new indication and emerging safety data in 2022.
February 2023, Nature reviews. Rheumatology,
Kevin L Winthrop
[Anti-rheumatic effect of JAK-inhibitors].
January 2012, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,
Kevin L Winthrop
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
January 2014, Journal of immunology research,
Kevin L Winthrop
JAK inhibitors and autoimmune rheumatic diseases.
April 2023, Autoimmunity reviews,
Kevin L Winthrop
The safety of JAK-1 inhibitors.
May 2021, Rheumatology (Oxford, England),
Kevin L Winthrop
Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease.
January 2019, Best practice & research. Clinical gastroenterology,
Kevin L Winthrop
Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders.
October 2023, Actas dermo-sifiliograficas,
Copied contents to your clipboard!